Mark Breidenbach
Stock Analyst at Oppenheimer
(1.65)
# 3,382
Out of 4,984 analysts
56
Total ratings
31.67%
Success rate
0.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $8.57 | +250.06% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.13 | +1,050.44% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $0.20 | +8,286.78% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $7.61 | +1,148.36% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $8.07 | +209.79% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.72 | +1,284.47% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $17.61 | +1,262.86% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.76 | +4,155.32% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.36 | +414.71% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.72 | +1,760.47% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $2.22 | +575.68% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.71 | +6,917.54% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.61 | +605,490.06% | 2 | May 12, 2020 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $8.57
Upside: +250.06%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.13
Upside: +1,050.44%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $0.20
Upside: +8,286.78%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $7.61
Upside: +1,148.36%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $8.07
Upside: +209.79%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.72
Upside: +1,284.47%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $17.61
Upside: +1,262.86%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.76
Upside: +4,155.32%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.36
Upside: +414.71%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.72
Upside: +1,760.47%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.22
Upside: +575.68%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.71
Upside: +6,917.54%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.61
Upside: +605,490.06%